EGFR and non-small cell lung carcinoma: Similarly, PAR2-mediated EGFR transactivation can regulate EGFR-related signaling and therefore we hypothesized that this transactivation might also bypass gefitinib-induced EGFR blockade to modulate NSCLC resistant to gefitinib.